PBMs: Merck-Medco in the Hot Seat

Brichacek,Andra;

News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

PBMs: Merck-Medco in the Hot Seat

October 1, 2001

By Andra Brichacek

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-01-2001

Volume 0

Issue 0

Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.

Articles in this issue

National Crisis Supercedes Coverage Debate

PBMs: Merck-Medco in the Hot Seat

AIDS Treatments: Discounts Here to Stay

Chaotic Content: Streamlined Solutions

Clinical Trial: FDA Stays Silent on Trovan Charges

National Crisis Supercedes Coverage Debate

A Five-Year Forecast: Clear Seas Ahead?

Weak Bones, Strong Market

Approvals: Novartis’ Silver Lining

Pfizer and others Pitch In

Oncology: EMEA Approval Lags

BioTech's New Business Model

Illegal Sales in India

Also Known As...The Value of Generic Names

Health Plan Premiums: Pharma Takes the Blame

Related Content

Survey Suggests Pharma Industry Still Struggling with Digital Transformation

Mike Hollan

November 22nd 2024

Article

The results say that the industry still lacks talent and skills in this area.

Key Findings of the NIAGARA and HIMALAYA Trials

Don Tracy, Associate Editor

November 8th 2024

Podcast

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

FDA Grants Accelerated Approval to Jazz Pharmaceuticals’ Ziihera for HER2-Positive Biliary Tract Cancer

Davy James

November 21st 2024

Article

Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) provides a chemotherapy-free treatment option for patients with HER2-positive biliary tract cancer, addressing a critical unmet need with promising efficacy and improved quality of life.

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Miranda Schmalfuhs

October 25th 2024

Podcast

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.